Exponent announces sale of BBI Group to Novo Holdings

Exponent announces that it has reached an agreement to sell BBI Group (“BBI”), a leading supplier of products and services to the global diagnostics and life sciences industries, to Novo Holdings A/S, a leading global life sciences investor, for an enterprise value of over £400 million.

Founded in 1986, BBI provides critical reagents and immunoassay development, lateral flow development, diagnostic manufacturing services, and smartphone reader technologies to a global blue-chip customer base that includes Thermo-Fisher, Merck and Siemens. The company’s market-leading brand, BBI Solutions, provides a range of products, including antibodies, antigens, labels, complementary reagents and point of care tests. BBI is headquartered in South Wales and employs over 400 employees across its sites in seven countries and four continents. Read more

Related Posts

UNE receives $10.8 million to establish new Center for Cell Signaling Research

The University of New England has received a five-year, $10.8 million award from the National Institutes of Health to support an...

18 January 2024

Jackson Lab opens $4.5M on-site child care center in Bar Harbor

Anewly constructed child care center on the Jackson Laboratory’s Bar Harbor campus is seen as an important draw for employees that also...

17 January 2024

From med tech to skin care: Top Gun names 41 startups to 2024 lineup

Out of 57 companies that applied to Maine’s 2024 Top Gun business accelerator program, 41 have been accepted and will receive help...

16 January 2024